Why the Creso Pharma (ASX:CPH) share price fell 9% before freezing

Creso Pharma shares came to a halt this afternoon, here's what is happening…

| More on:
A dollar sign embedded in ice, indicating a share price freeze or trading halt

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Creso Pharma Ltd (ASX: CPH) share price came under pressure this afternoon. This followed breaking news published by The Australian Financial Review involving the cannabis and psychedelics company's non-executive chair, Adam Blumenthal.

Shares in the small-cap company tumbled 9% to 12.3 cents apiece before being placed into a trading halt. The frozen share price will remain in place until Creso can respond to the ASX's price query.

However, the intriguing news today relates to the office raid of Mr Blumenthal.

Creso Pharma share price falls amid ASIC investigation at EverBlu

Investors weren't playing around this afternoon after they got word of what was going on in Sydney today. It appears shareholders were quite nervous about the news that Creso Pharma's non-exec chair, Blumenthal, had his office raided by the Australian Federal Police (AFP) today.

To be clear, the office raided was not that of Creso Pharma. Rather, it was Blumenthal's boutique corporate advisory company, EverBlu Capital.

According to reports, officers were adorning gloves and flicking through files to assist the Australian Securities and Exchange Commission (ASIC) with an investigation. Neither the AFP nor ASIC have shed any further light on exactly what the investigation is in relation to.

The EverBlue Capital team was involved in advising Creso Pharma on its bonus options issue in October. My colleague, Zach, covered this at the time, outlining how the financial instrument could be used to raise capital if exercised.

Talk about timing

As fate would have it, the precarious situation has come to light mere days after Creso Pharma handed down its trading update for Q4 FY21. Overall, the update was reasonably positive for the company, pushing The Creso Pharma share price higher.

Furthermore, the quarter saw the company achieve strong revenue growth in its Swiss operations. However, the market's sentiment might now be tainted by the latest developments involving Adam Blumenthal.

The Creso Pharma share price will remain halted until an announcement is provided, or until the commencement of trade on Thursday, 18 November 2021.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 36% in a year, why this $8 billion ASX 200 stock has still a 'strong growth forecast'

If you haven’t heard of this fast-rising ASX 200 stock yet, that’s about to change.

Read more »

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.
Healthcare Shares

Now trading at an 'attractive price', why CSL shares look set for a rebound

These leading fund managers expect CSL shares to put in a much stronger performance in FY 2026.

Read more »

three excited doctors with hands in the air
Healthcare Shares

Why Macquarie forecasts a 22% upside for this ASX All Ords healthcare stock

Macquarie expects a big rebound ahead for this ASX healthcare stock. But why?

Read more »

A young man wearing a black and white striped t-shirt looks surprised.
Healthcare Shares

Guess which ASX All Ords stock is jumping 9% on $1.6b market opportunity

This small cap is having a big day. But why?

Read more »

A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital
Healthcare Shares

75% upside: Broker tips two ASX healthcare shares

This broker sees big potential in these two Australian healthcare companies 

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

What does the Macquarie Hospital Claims Index mean for ASX 200 health insurance stocks?

Macquarie shares its view on Medibank Private and NIB Holdings.

Read more »

Two lab workers fist pump each other.
Broker Notes

What's JP Morgan's price target on CSL shares?

Are CSL shares undervalued or will they continue to underperform?

Read more »

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Healthcare Shares

2 ASX healthcare stocks making huge moves on big news

These shares are getting investors excited today. But why?

Read more »